mRNA vaccines have saved millions of lives during COVID-19, but have limitations such as waning immunity and complex production. Scientists are testing a new DoriVac platform that uses folded DNA nanostructures to better control the immune system's response. In early studies, DoriVac produced strong antibody and T cell responses in both mouse and human models. The researchers say this could lead to more stable and easier-to-produce vaccines. This technology aims to protect against diseases such as COVID-19, HIV and Ebola. DoriVac represents another leap beyond mRNA vaccines.